BAFF/APRIL system in pediatric OMS: Relation to severity, neuroinflammation, and immunotherapy

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Pranzatelli, Michael R ^a   Tate, Elizabeth D ^a   McGee, Nathan R ^a   Travelstead, Anna L ^a   Colliver, Jerry A ^a   Ness, Jayne M ^b   Ransohoff, Richard M ^c  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

BAFF R; Cerebrospinal fluid cytokines; Childhood neuroinflammatory disorders; Corticosteroids; Corticotropin; IVIg; Neuroblastoma; Opsoclonus myoclonus; Paraneoplastic syndrome; Rituximab

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; CORTICOSTEROID; CORTICOTROPIN; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN; RITUXIMAB; SECONDARY LYMPHOID TISSUE CHEMOKINE; STEROID;

ADOLESCENT; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOTHERAPY; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; OPSOCLONUS MYOCLONUS SYNDROME; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; INFANT; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MALE; OPSOCLONUS-MYOCLONUS SYNDROME; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84872175641     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-10     Document Type: Article

References (31)

1. Tate ED, Pranzatelli MR, Verhulst SJ, Markwell SJ, Franz DN, Graf WD, Joseph SA, Khakoo YN, Lo WD, Mitchell WG, Sivaswamy L. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol 2012, 27:875-884.
2. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004, 19:770-777.
3. Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Ransohoff RM, Ness JM, Colliver JA. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J Neuroimmunol 2012, 243:81-88.
4. Pranzatelli MR, Tate ED, Hoefgen ER, Verhulst SJ. Interferon-inducible protein 10 (CXCL10) is increased in the cerebrospinal fluid of children with opsoclonus-myoclonus syndrome. Ann Neurol 2007, Suppl 11:S112-S113.
5. Pranzatelli MR, Slev PR, Tate ED, Travelstead AD, Colliver JA, Joseph SA. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr Neurol 2011, 45:27-33.
6. Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: who's who?. Autoimmun Rev 2008, 7:267-271.
7. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
8. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011, 244:115-133.
9. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Kalled SL, Hess DM, Serafini B, Aloisi F, Wekerle H, Hohlfeld R, Meinl E. BAFF is produced by astrocytes and up-regulated in multiple sclerosis legions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
10. Thangarajh M, Kisiswa L, Pirskanen R, Hillert J. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. Scand J Immunol 2007, 65:461-466.
11. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007, 19:327-336.
12. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008, 10:R97.
13. Hamzaoui K, Houman H, Hentati F, Hamzaoui A. BAFF is up-regulated in central nervous system of neuro-Behcet's disease. J Neuroimmunol 2008, 200:111-114.
14. Hopia L, Thangarajh M, Khademi M, Laveskog A, Wallström E, Svenungsson E, Andersson M. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol 2011, 40:363-372.
15. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL, Mackay F, Mackay CR. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004, 173:807-817.
16. Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine 2008, 44:26-32.
17. Kivisäkk P, Liu Z, Trebst C, Tucky B, Wu L, Stine J, Mack M, Rudick RA, Campbell JJ, Ransohoff RM. Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods 2003, 29:319-325.
18. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:3692-3701.
19. Piazza F, DiFrancesco JC, Fusco ML, Corti D, Pirovano L, Frigeni B, Mattavelli L, Andreoni S, Frigo M, Ferrarese C, Tredici G, Cavaletti G. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J Neuroimmunol 2010, 220:104-107.
20. Ragheb S, Li Y, Simon K, Van Haerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011, 17:819-829.
21. Franciotta D, Di Stefano AL, Jarius S, Zardini E, Tavazzi E, Ballerini C, Marchioni E, Bergamaschi R, Ceroni M. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol 2011, 230:160-163.
22. Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009, 53:1-16.
23. Xiao Y, Motomura S, Podack ER. APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol 2008, 38:3450-3458.
24. Doi M, Takeda T, Sakurai Y, Kato J, Hayashi T, Fukuda K, Takase T, Shima M. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J Investig Allergol Clin Immunol 2010, 20:413-418.
25. Pranzatelli MR, Tate ED, Travelstead AL, Verhulst SJ. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS. Cytokine 2011, 53:384-389.
26. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005, 25:298-302.
27. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004, 63:1096-1103.
28. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007, 1110:426-432.
29. Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167.
30. Fühlhuber V, Bick S, Kirsten A, Hahn A, Gerriets T, Tschernatsch M, Kaps M, Preissner KT, Blaes F, Altenkämper S. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2009, 210:87-91.
31. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, Plebani A, Lougaris V, Quinti I, Thon V, Litzman J, Schlesier M, Warnatz K, Thiel J, Rolink AG, Eibel H. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012, 188:497-503.